Business Wire

THALES

6.8.2020 14:02:11 CEST | Business Wire | Press release

Share
Thales High Tech to Offer Thai Citizens One of the World’s Most Secure E-Passports

Even though the COVID-19 health crisis has been severely disrupting the global travel industry, in the past few months the DGM Consortium has continued its close collaboration with MOFA. Global teams were working remotely to deliver the project, supporting the Thai Government’s ‘Thailand 4.0’ vision to develop an innovative, digital economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005034/en/

The new Thai e-passport project was delivered on the 8th of July to MOFA and launched in an official inauguration ceremony conducted on the 5th of August in the presence of Minister Don Pramudwinai, Minister of Foreign Affairs of Thailand.

The Thai e-passport project is one of the largest passport programs for Thales worldwide, as it aims to provide Thai citizens superior technology and the highest possible level of security in a travel document.

The newly designed 64-page biometric travel document includes an e-Cover and a thin, flexible data page made of polycarbonate material. The reverse side of the data page features a high definition, true color UV picture of one of Bangkok’s most iconic landmarks, the Wat Arun temple. The security features visible on the data page include an additional secondary image of the citizen perforated in the semi-transparent window; as well as the traditional Thai four-petal lotus symbol, the line-pra-jum-yam, embossed using Thales’ Secure Surface technology.

Designed to counter new types of forgeries, Thales Secure Surface provides optical elements with light reflective and animation effects revealed by tilting a document in different angles. This visible security feature allows fast and efficient verification by border authorities.

An additional perceptible feature is the tactile signature of the citizen embossed on the data page. Biometric data is securely embedded into the passport chip using Thales’ secure embedded software. This software provides strong security for identification and protection of citizens’ privacy.

The technological features of the passport ensures secure and fast border crossing, while complying with all relevant data protection laws in Thailand and is fully compliant to the highest security standards recommended by the International Civil Aviation Organisation (ICAO).

Since the project’s inception, Thales has trained 250 local experts in its passport issuance technologies. Over the next seven years, Thales will be operating know-how transfer and upskilling more than 500 Thai nationals in its technologies, thus significantly contributing to the local economy.

Thales has been a dedicated partner to Thailand for almost 50 years in industry sectors ranging from defence to air traffic management and ground transportation. Aligning with this vision Thales will henceforth be providing its digital identity and biometrics expertise to the Thai Ministry of Foreign Affairs, making the Group their trusted partner as they deliver a highly-secure and modern passport for their citizens.

“I am delighted that Thales has successfully delivered this new generation passport to Thai citizens and helped the Ministry of Foreign Affairs (MOFA) strengthen homeland protection and safeguard their citizens’ identities. Throughout the last few months amidst the global COVID-19 pandemic, we have continued our close collaboration with MOFA and worked tirelessly to deliver this milestone. Thai citizens now possess one of the world’s most sophisticated e-passports that integrate biometrics and other high-security features that will provide a seamless and secure travel experience. We will continue to build local expertise in passport issuance with training and transfer-of-technology aligned with our commitment to upskilling the Thai workforce as Thailand moves towards a digital future.” Massimo Marinzi, Country Director, Thales in Thailand

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group
Download HD photos

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye